Lineage Cell Therapeutics (LCTX) Projected to Post Earnings on Tuesday

Key Points

• Lineage Cell Therapeutics is expected to report its Q2 2025 earnings on August 12, with analysts anticipating a loss of ($0.02) per share and revenue of $1.47 million.
• The company's stock price recently increased to $0.99, with a market capitalization of $226.05 million and institutional investors owning approximately 62.47% of its shares.
• Analysts maintain a positive outlook with a consensus target price of $4.20, and several reports rate the stock as a "buy."

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $1.47 million for the quarter.

Lineage Cell Therapeutics Price Performance

Lineage Cell Therapeutics stock traded up $0.03 during trading on Wednesday, reaching $0.99. 1,057,543 shares of the company were exchanged, compared to its average volume of 1,929,023. The stock's 50 day simple moving average is $0.92 and its two-hundred day simple moving average is $0.66. The company has a market capitalization of $226.05 million, a P/E ratio of -12.37 and a beta of 1.66. Lineage Cell Therapeutics has a 52-week low of $0.37 and a 52-week high of $1.21.

Institutional Trading of Lineage Cell Therapeutics

A hedge fund recently raised its stake in Lineage Cell Therapeutics stock. Rhumbline Advisers boosted its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 9.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,447 shares of the company's stock after buying an additional 18,092 shares during the period. Rhumbline Advisers owned about 0.09% of Lineage Cell Therapeutics worth $91,000 as of its most recent SEC filing. Institutional investors own 62.47% of the company's stock.

Analysts Set New Price Targets

LCTX has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a report on Monday, June 23rd. D. Boral Capital reissued a "buy" rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Lineage Cell Therapeutics presently has an average rating of "Buy" and a consensus target price of $4.20.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.